[
  {
    "ts": null,
    "headline": "Merck Gains FDA Approval for KEYTRUDA QLEX and Supports Dividend Appeal",
    "summary": "Merck & Co., Inc. (NYSE:MRK) is one of the 13 Best Fortune 500 Dividend Stocks to Invest In. Following a decline in revenue in the second quarter of 2025, the company received the FDA approval for KEYTRUDA QLEX™ injection. Merck & Co., Inc. (NYSE:MRK) reported an Adjusted EPS of $2.13 for the second quarter of 2025. […]",
    "url": "https://finnhub.io/api/news?id=ee292747f3212dbaa2303ebd594da58d0b07f6c1f5f09e275be68f33b23c8233",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758670864,
      "headline": "Merck Gains FDA Approval for KEYTRUDA QLEX and Supports Dividend Appeal",
      "id": 136858161,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck & Co., Inc. (NYSE:MRK) is one of the 13 Best Fortune 500 Dividend Stocks to Invest In. Following a decline in revenue in the second quarter of 2025, the company received the FDA approval for KEYTRUDA QLEX™ injection. Merck & Co., Inc. (NYSE:MRK) reported an Adjusted EPS of $2.13 for the second quarter of 2025. […]",
      "url": "https://finnhub.io/api/news?id=ee292747f3212dbaa2303ebd594da58d0b07f6c1f5f09e275be68f33b23c8233"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co., Inc. (MRK) Received FDA Approval For Keytruda Qlex, Cutting Infusion Time to 2 Minutes",
    "summary": "In this article, we will be taking a look at the 10 Best Pharma Stocks to Buy According to Billionaires. Merck & Co., Inc. is placed fourth among them. Merck & Co., Inc. (NYSE:MRK), a global biopharmaceutical company founded in 1891 and headquartered in Rahway, New Jersey, continues to strengthen its leadership in oncology and […]",
    "url": "https://finnhub.io/api/news?id=96742b4130719a0aafc93e6c182c00258ebb4305a6cd69231ce823b2e8e4d7d5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758668558,
      "headline": "Merck & Co., Inc. (MRK) Received FDA Approval For Keytruda Qlex, Cutting Infusion Time to 2 Minutes",
      "id": 136858162,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "In this article, we will be taking a look at the 10 Best Pharma Stocks to Buy According to Billionaires. Merck & Co., Inc. is placed fourth among them. Merck & Co., Inc. (NYSE:MRK), a global biopharmaceutical company founded in 1891 and headquartered in Rahway, New Jersey, continues to strengthen its leadership in oncology and […]",
      "url": "https://finnhub.io/api/news?id=96742b4130719a0aafc93e6c182c00258ebb4305a6cd69231ce823b2e8e4d7d5"
    }
  },
  {
    "ts": null,
    "headline": "The Outlook For Precigen",
    "summary": "Precigen stock jumps after FDA approves Papzimeos for RRP. Read about its market potential, efficacy vs rivals, and what this means for investors.",
    "url": "https://finnhub.io/api/news?id=97a14adbab23eb3ee5880c5b97013024dfe9605aa30a70a543cf675eaaee7f88",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758651503,
      "headline": "The Outlook For Precigen",
      "id": 136856667,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2194222145/image_2194222145.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Precigen stock jumps after FDA approves Papzimeos for RRP. Read about its market potential, efficacy vs rivals, and what this means for investors.",
      "url": "https://finnhub.io/api/news?id=97a14adbab23eb3ee5880c5b97013024dfe9605aa30a70a543cf675eaaee7f88"
    }
  },
  {
    "ts": null,
    "headline": "AZN Gets CHMP Nod for Label Expansion of Koselugo & Tezspire",
    "summary": "AstraZeneca wins CHMP backing for label expansions of Koselugo in adult NF1 PN patients and Tezspire in chronic rhinosinusitis with nasal polyps.",
    "url": "https://finnhub.io/api/news?id=912a243ac9e4d8096785ffa0f0b3d7fe54fe56b5c80b56b657b4054670bf30bc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758643020,
      "headline": "AZN Gets CHMP Nod for Label Expansion of Koselugo & Tezspire",
      "id": 136855552,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "AstraZeneca wins CHMP backing for label expansions of Koselugo in adult NF1 PN patients and Tezspire in chronic rhinosinusitis with nasal polyps.",
      "url": "https://finnhub.io/api/news?id=912a243ac9e4d8096785ffa0f0b3d7fe54fe56b5c80b56b657b4054670bf30bc"
    }
  },
  {
    "ts": null,
    "headline": "Merck (MRK) Valuation in Focus After FDA Greenlights Keytruda QLEX Cancer Therapy",
    "summary": "If you have been watching Merck (MRK) lately, the recent FDA approval for Keytruda QLEX has probably caught your eye. This new subcutaneous version of their flagship cancer drug is now approved for use across 38 solid tumor indications. This is a significant milestone for both patients and the company’s long-term positioning. For investors, the story is as much about future-proofing as it is about the present, with Merck racing to shore up revenue before the original IV Keytruda faces generic...",
    "url": "https://finnhub.io/api/news?id=4092d0e2b74f497cd9321e00fbe987f47b1ff8473c2e53f3242b458ff6edf659",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758626282,
      "headline": "Merck (MRK) Valuation in Focus After FDA Greenlights Keytruda QLEX Cancer Therapy",
      "id": 136850667,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "If you have been watching Merck (MRK) lately, the recent FDA approval for Keytruda QLEX has probably caught your eye. This new subcutaneous version of their flagship cancer drug is now approved for use across 38 solid tumor indications. This is a significant milestone for both patients and the company’s long-term positioning. For investors, the story is as much about future-proofing as it is about the present, with Merck racing to shore up revenue before the original IV Keytruda faces generic...",
      "url": "https://finnhub.io/api/news?id=4092d0e2b74f497cd9321e00fbe987f47b1ff8473c2e53f3242b458ff6edf659"
    }
  },
  {
    "ts": null,
    "headline": "Merck and Siemens extend digital transformation partnership in life sciences",
    "summary": "The two companies will leverage automation, data and AI to streamline drug discovery, development and manufacturing.",
    "url": "https://finnhub.io/api/news?id=dcef359f8560d877ca09331b6fb55bc399cf0eb21b180481eec6620f8ce8756b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758625403,
      "headline": "Merck and Siemens extend digital transformation partnership in life sciences",
      "id": 136850668,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The two companies will leverage automation, data and AI to streamline drug discovery, development and manufacturing.",
      "url": "https://finnhub.io/api/news?id=dcef359f8560d877ca09331b6fb55bc399cf0eb21b180481eec6620f8ce8756b"
    }
  },
  {
    "ts": null,
    "headline": "Variational AI Enters Collaboration with Merck to Apply Generative AI to Drug Discovery",
    "summary": "VANCOUVER, British Columbia, September 23, 2025--Variational AI enters Collaboration with Merck to apply Generative AI Drug Discovery platform to design and optimize novel small molecule therapeutics",
    "url": "https://finnhub.io/api/news?id=c127883d21762ec12f4b4f2b4e3e4ba77733682dd3778ea6f424524ecfee513b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758625200,
      "headline": "Variational AI Enters Collaboration with Merck to Apply Generative AI to Drug Discovery",
      "id": 136850669,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "VANCOUVER, British Columbia, September 23, 2025--Variational AI enters Collaboration with Merck to apply Generative AI Drug Discovery platform to design and optimize novel small molecule therapeutics",
      "url": "https://finnhub.io/api/news?id=c127883d21762ec12f4b4f2b4e3e4ba77733682dd3778ea6f424524ecfee513b"
    }
  },
  {
    "ts": null,
    "headline": "FDA clears under-the-skin Keytruda; MBX shares double on study data",
    "summary": "The clearance of Keytruda QLEX follows similar approvals for Bristol Myers and Roche. Elsewhere, MBX’s parathyroidism drug impressed investors and Roche claimed success in a breast cancer study.",
    "url": "https://finnhub.io/api/news?id=fc1c2f6a19ca85c16e75d98a555baaaae376a77d86c82e903c4f80a5269f8742",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758617640,
      "headline": "FDA clears under-the-skin Keytruda; MBX shares double on study data",
      "id": 136850670,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The clearance of Keytruda QLEX follows similar approvals for Bristol Myers and Roche. Elsewhere, MBX’s parathyroidism drug impressed investors and Roche claimed success in a breast cancer study.",
      "url": "https://finnhub.io/api/news?id=fc1c2f6a19ca85c16e75d98a555baaaae376a77d86c82e903c4f80a5269f8742"
    }
  }
]